Full prescribing information can be found in product labeling at or by calling Bioventus Customer Care at 0800 05 16 384 (UK)/ 1800 552 197 (IR). Some patients may be sensitive to the ultrasound gel. Safety and effectiveness have not been established for individuals lacking skeletal maturity, pregnant or nursing women, patients with cardiac pacemakers, on fractures due to bone cancer, or on patients with poor blood circulation or clotting problems. There are no known contraindications for the EXOGEN device. EXOGEN is also indicated for the acceleration of fresh fracture heal time, repair following osteotomy, repair in bone transport procedures and repair in distraction osteogenesis procedures. For more information, visit and follow the company on Twitter the Bioventus logo, and EXOGEN are registered trademarks of Bioventus LLC.ĮXOGEN is indicated for the non-invasive treatment of osseous defects (excluding vertebra and skull) that includes the treatment of delayed unions, nonunions,* stress fractures and joint fusion. Built on a commitment to high quality standards, evidence-based medicine and strong ethical behavior, Bioventus is a trusted partner for physicians worldwide. The orthobiologic products from Bioventus include offerings for osteoarthritis, surgical and non-surgical bone healing. Its mission is to make a difference by helping patients resume and enjoy active lives. “Both the updated clinical and economic evidence presented in this amended guidance to MTG12 strongly support a clinicians’ decision to prescribe EXOGEN and, most importantly, provide positive outcomes for patients.”īioventus is an orthobiologics company that delivers clinically proven, cost-effective products that help people heal quickly and safely. “ EXOGEN has also been a proven adjunctive therapy for surgically treated fractures and has many Level-1 studies showing its positive effect on fracture healing,” said Peter Shaw, MBBS DRCOG, Chief Medical Officer, Bioventus. ”This updated guidance from NICE continues its previous recommendation for use and underscores the cost savings gained by patients suffering from nonunions which provides significant economic relief to the health care system in the United Kingdom.” “ EXOGEN has been a proven alternative to patients seeking to heal long bone nonunion fractures and avoid surgery for many years,” said Tony Bihl, CEO, Bioventus. The next issue of Financial Post Top Stories will soon be in your inbox. If you don't see it, please check your junk folder.
0 Comments
Leave a Reply. |